Sellas Stock 346% Year Near Final REGAL Deaths Ahead
Sellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
Choosing the right investment app can be daunting for beginners. We break down the best options to help you start investing confidently.
24,582 articlesSellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
Gen Z buyers are turning to Midwest towns where median prices sit well below coastal metros. This shift signals a maj...
ADP’s April payrolls show the private sector added 109,000 jobs, surpassing forecasts and painting a picture of a res...
ZoomInfo's go-to-market approach is evolving as 2026 unfolds. This analysis breaks down the GTM moves behind the earn...
York Space Systems stock tumbled after a disappointing quarterly report. This guide explains what happened, why it ma...
A surprising analyst upgrade helped StubHub Holdings stock crush expectations this week. This article breaks down the...
A disciplined, long-term plan can turn $1,000 into meaningful gains with AI-driven leaders. Explore three core stocks...
Cem Karsan warns that the S&P 500 may suffer a prolonged real-term decline similar to a historic 14-year period, as i...
When two tech and space giants collaborate, the market watches closely. This article breaks down what a hypothetical ...
Energy income investors face a critical test as crude prices swing. This report examines the dividend safety check: e...
As companies rush to deploy AI, hundreds of pilots risk wasting resources and diluting strategy. Analysts warn that t...
Investors are weighing the risks and potential rewards as Netflix prepares for its July earnings. This guide breaks d...